Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | KCNJ6 | P48051 | 9/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 9/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447025 | 0.97 | KCNJ6 (0.39) | CYP3A4GAACYP2C19NTRK1KCNJ6 | |
| SCHEMBL5223227 | 0.87 | MAPK14 (0.35) | NTRK1KCNJ6KCNJ3KCNJ5MEN1 | |
| SCHEMBL5223671 | 0.81 | CYP3A4 (0.48) | CYP3A4GAACYP2C19NTRK1KCNJ6 | |
| SCHEMBL5331514 | 0.80 | NTRK1 (0.42) | CYP3A4GAACYP2C19NTRK1KCNJ6 | |
| SCHEMBL5222409 | 0.80 | CYP3A4 (0.44) | CYP3A4GAACYP2C19NTRK1KCNJ6 | |
| SCHEMBL5218916 | 0.78 | ALDH1A1 (0.43) | GAAMEN1KMT2AMAPT | |
| SCHEMBL5221857 | 0.78 | NTRK1 (0.45) | CYP3A4GAACYP2C19NTRK1KCNJ6 | |
| SCHEMBL5225195 | 0.78 | LMNA (0.35) | MEN1KMT2AMAPTHTR2AHTR2C | |
| SCHEMBL5224271 | 0.78 | MEN1 (0.35) | MEN1KMT2AMAPTMAPK14HTR2A | |
| SCHEMBL5223942 | 0.77 | RAB9A (0.48) | GAAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | LE GRAND DARREN M | 2007-02-22 | — | — | US | claimed |
| EP-1663966-B1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | LE GRAND DARREN M | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | CCR1, CCR3, CCR9 | CYP3A4 2159/4885GAA 2907/4885CYP2C19 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.